Matthew Dryden Selected Research

Soft Tissue Infections

2/2022	Impact of Underlying Comorbidities on Outcomes of Patients Treated with Ceftaroline Fosamil for Complicated Skin and Soft Tissue Infections: Pooled Results from Three Phase III Randomized Clinical Trials.
1/2022	Novel techniques in the treatment of skin and soft tissue infection.
1/2022	Treatment outcomes of secondary bacteraemia in patients treated with ceftaroline fosamil: pooled results from six phase III clinical trials.
9/2020	Baseline Characteristics and Outcomes Among Patients with Complicated Skin and Soft Tissue Infections Admitted to the Intensive Care Unit: Analysis of the Phase 3 COVERS Randomized Trial of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam.
4/2017	Reactive oxygen therapy: a novel therapy in soft tissue infection.
12/2016	A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities.
8/2016	Early clinical assessment of response to treatment of skin and soft-tissue infections: how can it help clinicians? Perspectives from Europe.
7/2016	Hot topics in the diagnosis and management of skin and soft-tissue infections.
7/2013	Tigecycline: an antibiotic for the twenty-first century.
6/2005	Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matthew Dryden Research Topics

Disease

19	Infections 04/2020 - 02/2004
11	Soft Tissue Infections 02/2022 - 02/2004
6	Wounds and Injuries (Trauma) 03/2018 - 09/2014
5	Pneumonia (Pneumonitis) 01/2022 - 02/2004
4	Sepsis (Septicemia) 06/2019 - 11/2011
3	Ulcer 03/2018 - 09/2014
2	Inflammation (Inflammations) 09/2020 - 12/2016
2	Respiratory Tract Infections (Respiratory Tract Infection) 01/2020 - 01/2017
2	Osteomyelitis 08/2019 - 01/2014
2	Burns 03/2018 - 04/2017
2	Healthcare-Associated Pneumonia 01/2018 - 08/2017
1	Cross Infection (Nosocomial Infection) 11/2021
1	Wound Infection (Wound Infections) 04/2020
1	Fatigue 04/2020
1	Diarrhea 04/2020
1	Systemic Inflammatory Response Syndrome (Sepsis Syndrome) 06/2019
1	Disease Progression 02/2019
1	Endocarditis 01/2019
1	Rhinosinusitis 03/2018
1	Fibrosis (Cirrhosis) 03/2018
1	Bronchiectasis 03/2018
1	Chronic Bronchitis 03/2018
1	Cystitis 03/2018
1	Body Weight (Weight, Body) 01/2018
1	Persistent Infection 01/2017
1	Communicable Diseases (Infectious Diseases) 11/2016
1	Diabetic Foot 01/2014
1	Infectious Arthritis (Septic Arthritis) 01/2014
1	Bacterial Infections (Bacterial Infection) 01/2014
1	Septic Shock (Toxic Shock Syndrome) 01/2014
1	Intraabdominal Infections 07/2013
1	Bacterial Meningitis 10/2011
1	Superinfection 12/2009

Drug/Important Bio-Agent (IBA)

13	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 12/2009
10	Vancomycin FDA LinkGeneric 02/2022 - 06/2005
8	iclaprim (AR 100)IBA 04/2020 - 08/2017
5	Ceftaroline FDA Link 02/2022 - 12/2016
3	Aztreonam FDA LinkGeneric 02/2022 - 12/2016
2	Biomarkers (Surrogate Marker)IBA 02/2019 - 01/2014
2	Pharmaceutical PreparationsIBA 01/2018 - 11/2011
2	Linezolid (Zyvox)FDA Link 06/2005 - 02/2004
1	C-Reactive ProteinIBA 01/2020
1	DNA-Directed DNA Polymerase (Polymerases, DNA)IBA 01/2019
1	Oxygen (Dioxygen)IBA 04/2017
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2017
1	Methicillin (Metin)FDA Link 08/2016
1	Local Anti-Infective Agents (Antiseptics)IBA 01/2015
1	SuspensionsIBA 09/2014
1	ProcalcitoninIBA 01/2014
1	Tigecycline (Tygacil)FDA Link 07/2013
1	Amoxicillin (Wymox)FDA LinkGeneric 11/2011
1	Tazobactam Drug Combination Piperacillin (Zosyn)FDA LinkGeneric 11/2011
1	Moxifloxacin (Avelox)FDA Link 11/2011
1	Clavulanic Acid (Potassium Clavulanate)FDA LinkGeneric 11/2011
1	TeicoplaninIBA 02/2004

Therapy/Procedure

5	Drug Therapy (Chemotherapy) 08/2019 - 04/2015
5	Therapeutics 06/2019 - 08/2016
1	Debridement 01/2022
1	Long-Term Care 11/2021
1	Inappropriate Prescribing 12/2009